Related Experiment Video
Updated: Aug 24, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Antithrombotic therapy with low molecular weight heparin in cancer patients
1Department of Surgical Oncology and Technology, Imperial College, Hammersmith Hospital, Du Cane Road, W12 0NN, London, UK.
Abstract:
Thrombosis is a common complication in patients with cancer. Low molecular weight heparins have been shown to be effective in both the prevention and treatment of venous thromboembolism in the cancer patient. More recently, studies have confirmed the benefits of extended duration of LMWH in the primary prevention of VTE after cancer surgery and for up to six months therapy for acute symptomatic VTE treatment. Beyond these well established uses for LMWH in the prevention and treatment of thrombosis in cancer patients, contemporary studies have demonstrated that LMWH therapy can prolong survival in patients with solid tumour malignant disease.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
